Introduction
Human chronic viral infections including, hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) represent serious global health problems. 1, 2 Lymphocytic choriomeningitis virus clone-13 (LCMV cl-13) has been used as a model to gain insight into the mechanisms that contribute to viral persistence. In LCMV cl-13 infection, early exposure to high viral loads leads to increased expression of inhibitory receptors, including programmed cell death protein-1 (PD-1), 3 prostaglandin E 2 receptors, 4 cytotoxic T-lymphocyte-associated protein-4 5 and T-cell immunoglobulin mucin-3 6 on activated T cells, and expression of immunosuppressive cytokines including interleukin-10 and transforming growth factor-b, leading to T-cell and B-cell dysfunction. 7, 8 It is known that virus-specific T cells are present in patients with chronic infections;
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however, they are functionally exhausted (T-cell exhaustion). In T-cell exhaustion, 9 virus-specific cytotoxic T lymphocytes have diminished cytotoxic effector activity, progressively lose effector cytokine secretion of interleukin-2, tumour necrosis factor-a (TNF-a) and interferon-c (IFN-c), 10 have decreased proliferative capacity 11 and can be physically deleted from the immune repertoire. 12 Treatment with antibodies to PD-1 : programmed death ligand 1 or the receptor to interleukin-10 has been reported to prevent T-cell exhaustion and lead to clearance of LCMV cl-13. 3, [13] [14] [15] The effects of T-cell exhaustion have been shown to be reversible and more importantly responsive to treatment, making T-cell exhaustion a prime target for therapeutic intervention to improve treatment of patients with chronic viral infection. 13, 14, 16 
CD4
+ CD25 + FoxP3 + regulatory T (Treg) cells are known to contribute to viral persistence through inhibition of both innate and adaptive immunity. [17] [18] [19] Previous studies have shown that depletion of Treg cells enhances immunity against HBV 20 and HCV. 21 Recently, a subset of inducible and natural Treg cells expressing the T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) have been identified. 22 Ligation of TIGIT to CD155 on antigen-presenting cells (APC) leads to increased expression of FGL2, resulting in suppression of both T helper type 1 (Th1) and Th17 responses in vivo. 22 We and others have shown that FGL2 exerts its immunosuppressive activity following binding to its cognate receptor FccRIIB/RIII, which is expressed on APC, natural killer cells and B cells. Although it has been shown that naive T cells do not express FccRIIB/RIII, in the setting of viral infection, activated T cells may express FccRIIB/RIII. Hence, in chronic viral disease, the T-cell inhibitory effects may be both direct and indirect. [23] [24] [25] Engagement of Fcc receptors have been implicated in the pathogenesis of a number of immunologically mediated diseases [26] [27] [28] and regulates the response to parasitic 29 and bacterial 30, 31 infections. We and others have reported that FGL2 contributes to the pathogenesis of fulminant viral hepatitis induced by mouse hepatitis virus-3 and an acute self-limiting viral hepatitis caused by LCMV WE. 22, 32, 33 In the current study, we used two complementary but independent approaches to evaluate whether inhibition of FGL2 would restore innate and adaptive immunity leading to clearance of chronic LCMV cl-13 infection. We first showed that targeted deletion of fgl2 (fgl2 À/À ) enhanced maturation of macrophage and dendritic cells (DC), antiviral T-cell and B-cell immunity, resulting in clearance of chronic LCMV cl-13 infection. Second, the use of neutralizing antibodies to FGL2 and the receptor for FGL2, FccRIIB/RIII, both before infection and during established chronic infection restored CD4 + and CD8 + Tcell responses, resulting in clearance of LCMV cl-13. These studies confirm the role of FGL2 in chronic viral persistence and the potential to disrupt the FGL2-FccRIIB/RIII pathway as a novel therapeutic strategy to treat humans with chronic infections.
Materials and methods

Mice
The fgl2 À/À mice were generated as described previously. 34 Eight-to ten-week-old weight-matched C57BL/6 littermate fgl2 +/+ and fgl2 À/À female mice received 2 9 10 6 plaque-forming units (PFU) of LCMV cl-13. Animal protocols were approved by the University Health Network in accordance with guidelines set by the Canadian Council on Animal Care.
LCMV virus and viral titres
LCMV cl-13 was obtained as a gift from the laboratory of Dr M. Oldstone (The Scripps Research Institute, La Jolla, CA) and was propagated in BHK-21 cells (ATCC # CCL-10). 15 Mice were infected intravenously with LCMV and at defined time-points blood samples were collected into heparinized microvettes (Sarstedt, N€ umbrecht, Germany) as previously described. 33 Blood was centrifuged and plasma was collected. Tissues were harvested and snap-frozen in liquid nitrogen. Viral titres were determined on MC57 cells (ATCC # CRL-2295) using focus-forming assay. 35 Total LCMV-specific IgG detection An LCMV antibody ELISA was used for the detection of total LCMV-specific antibodies. 36 The absorbance value measured at 450 nm correlated with the captured total LCMV-specific antibody within plasma samples. The dilution series for each plasma sample was plotted and read where the dilution and observed absorbance values had a linear relationship with one another. Samples were expressed as a fold increase from naive absorbance.
Neutralizing antibody detection
LCMV neutralizing antibody titres were quantified in plasma from LCMV cl-13 infected mice using a plaque reduction assay. 37 Plasma was diluted 1 : 10 in complete a-modified Eagle's minimum essential medium supplemented with 2% fetal bovine serum and was serially diluted and mixed with 100 PFU of LCMV cl-13 for 1 hr at 37°. Following incubation, samples were added to MC57 cells and plaques were visualized using a standard focus-forming assay. 35 LCMV ex vivo peptide re-stimulation Splenic mononuclear cells were isolated as previously described 38 and stimulated with 10 µg/ml of the MHC class I peptide glycoprotein GP [33] [34] [35] [36] [37] [38] [39] [40] [41] or nucleoprotein NP 396-404 for 6 hr as previously described. [39] [40] [41] The LCMV peptide GP [33] [34] [35] [36] [37] [38] [39] [40] [41] H-2Db (KAVYNFATC) and NP 396-404 H-2Db (FQPQNGQFI) was synthesized by Anaspec Inc. (Fremont, CA). Brefeldin A (Sigma-Aldrich, St Louis, MO) was added to cultures after 1 hr of peptide re-stimulation for 5 hr at a final concentration of 10 µg/ ml. Flow cytometry was used to assess the frequency of splenic mononuclear cells producing IFN-c following ex vivo peptide re-stimulation.
Macrophage and DC isolation
Macrophages (CD11b + NK1.1 À ) and DC (CD11c + ) were isolated as previously described. 33, 42 Following incubation for 20 min with 5% mouse serum (Cedarlane Laboratories, Burlington, ON, Canada) in PBS at 4°, splenic mononuclear cells were fixed with 2% paraformaldehyde in PBS solution (Santa Cruz Biotechnology, Dallas, TX) for 20 min and stained with antibodies and gated as shown in the Supplementary material (Fig. S1 ).
Flow cytometry
Antibodies. Antibodies used for flow cytometry: The following antibodies were purchased from eBioscience (San Diego, CA) and were used to stain cells for FACS analysis as described below: Peridinin chlorophyll protein (PerCP) -Cy5.5-CD3e (Clone 17A2), fluorescein isothiocyanate (FITC) -CD4 (Clone GK1. Tetramers. Biotinylated MHC-I monomers (GP [33] [34] [35] [36] [37] [38] [39] [40] [41] were provided by the NIH Tetramer Core Facility, Emory University (Atlanta, GA). MHC-I monomers were tetramerized with streptavidin-PE according to NIH Tetramer Core Facility instructions. Fixable viability dye eFluor 450 (eBioscience) was used to confirm cell viability. Tetramer staining was performed on freshly isolated and unstimulated cells.
Cell staining. Mononuclear cells were isolated from the spleen, washed and resuspended in FACS buffer (PBS containing 1% fetal calf serum and 1 mM EDTA) at a final concentration of 1 9 10 7 cells/ml. Cells were treated with CD16/CD32 to block non-specific binding to Fcreceptors. Cells were surface stained with antibodies and LCMV-specific tetramers. Cells were then fixed with 2% paraformaldehyde. FACS analysis was performed using a BD LSRII Flow Cytometer and data were analysed using FLOWJO software (Tree Star Inc., Ashland, OR). Live cells were discriminated according to forward-scatter and sidescatter parameters and a fixable viability dye (eBioscience).
In vivo antibody treatment
The monoclonal antibody 9D8 was generated as previously described. 43 The effects of 9D8 on both the innate and adaptive immune systems are shown in the Supplementary material (Fig. S2) 
FGL2 ELISA
Plasma levels of FGL2 were quantified as previously described. 33 Briefly, plates were coated and incubated overnight with 1 ng/ml monoclonal anti-FGL2 (6H12) (IgG1) as a capture antibody. Plasma samples (50 µl) were added to each well, and following 1 hr incubation at 37°and three washes with Tris-buffered saline, the wells were incubated with 2 µg/ml polyclonal rabbit anti-FGL2 antibody for 2 hr at 37°. The plate was washed again and polyclonal anti-FGL2 binding was detected with secondary horseradish peroxidase-conjugated antirabbit antibody. Tetrametylbenzidine was then added and absorbance was measured at 450 nm using an ELISA plate reader. Levels of FGL2 were undetectable in the plasma of fgl2 À/À mice both before and after LCMV infection. Immunohistochemistry and morphometric analysis
The fgl2 +/+ mice and fgl2 À/À mice were infected intravenously with 2 9 10 6 PFU of LCMV cl-13. Tissues were frozen in Optimal Cutting Temperature compound (Sakura Finetek, Alphen aan den Rijn, the Netherlands) and 5-µm thick tissue sections were stained with a rat antibody to the nucleoprotein of LCMV (VL4) provided as a gift from Dr P. Ohashi (Princess Margaret Hospital, Toronto, ON, Canada). The tissues were then incubated with a horseradish peroxidase-conjugated secondary antirat IgG antibody that allowed for colour development after addition of substrate 3,3 0 -diaminobenzidine (Zymed, San Francisco, CA). Morphometric analysis for LCMV nucleoprotein (NP) was performed in liver at days 28 and 56 p.i. as previously described. 33 Slides were digitally scanned and the number of LCMV NP + cells was quantified by morphometric analysis using Spectrum V.10.2.2.2317 (Aperio Technologies Inc., Vista, CA). The number of LCMV NP + cells was expressed as a percentage of total cells. Control uninfected fgl2 +/+ and fgl2
livers were used as a control and did not stain positive for LCMV NP.
Statistics
Statistical significance was assessed using the analysis of variance or a Student's t-test. Statistical analysis was performed using PRISM 5 software (Graphpad Software Inc., San Diego, CA). Differences with P ≤ 0Á05 were considered statistically significant.
Results
LCMV cl-13 infection leads to increased expression of FGL2
Following infection with 2 9 10 6 PFU of LCMV cl-13 intravenously, increased plasma levels of FGL2 were detected in fgl2 +/+ mice by day 7 p.i., reaching maximum levels on day 10 p.i. (52-fold) and remained persistently elevated until day 56 p.i., although differences were only statistically significant until day 42 p.i. (Fig. 1 ).
Targeted deletion of fgl2 leads to clearance of LCMV cl-13
To examine the effect of deletion of fgl2 on viral clearance, both fgl2 +/+ and fgl2 À/À mice were infected intravenously with LCMV cl-13 and viral titres were measured in plasma (Fig. 2a) , lung ( Fig. 2b ) and liver ( Fig. 2c ) using a focus-forming assay. On day 28 p.i., the titres of LCMV cl-13 were significantly lower in the plasma (P < 0Á005), lung (P < 0Á05) and liver (P < 0Á005) of fgl2 À/À mice compared with fgl2 +/+ mice. Furthermore, by day 56 p.i., all fgl2 À/À mice had undetectable virus from the lung, liver and plasma whereas fgl2 +/+ mice remained persistently infected. To confirm that fgl2 À/À mice had cleared LCMV cl-13, liver tissues were stained for LCMV nucleoprotein and the percentage of LCMV + cells was analysed by morphometric analysis at days 28 and 56 p.i. Consistent with the focus-forming assay, morphometric analysis revealed that LCMV antigen was undetectable in the livers of fgl2 À/À mice at day 56 p.i., whereas LCMV NP antigen was detected in fgl2 +/+ mice indicating LCMV cl-13 viral clearance in fgl2 À/À mice ( Fig. 2d ,e). and fgl2 À/À mice both before infection and at day 2 p.i.
Before infection, macrophage ( Fig. 3a) and DC ( Fig. 3c ) expression of CD80, CD86 and MHC-II were equivalent in DCs and macrophages isolated from both fgl2 +/+ and fgl2 À/À mice. However, on day 2 p.i., the total number of macrophages and DC expressing CD80, CD86 and MHC-II were significantly increased in fgl2 À/À mice compared with fgl2 +/+ mice (Fig. 3b,d ) indicating enhanced maturation of APC isolated from fgl2 À/À mice p.i.
Targeted deletion of fgl2 leads to increased numbers of virus-specific CD8 + T cells following infection with LCMV cl-13
To determine whether FGL2 affected the number of LCMV-specific CD8 + T cells, fgl2 À/À mice and fgl2 +/+ mice were infected with 2 9 10 6 PFU of LCMV cl-13 and 28, and were significantly increased at day 56 compared with fgl2 +/+ mice (Fig. 4a,b) . The effects of targeted deletion of fgl2 on LCMV-specific CD8 + T-cell effector function was determined by measurement of IFN-c and TNF-a production in CD8 + T cells following ex vivo peptide re-stimulation with the MHC-I-restricted peptide GP [33] [34] [35] [36] [37] [38] [39] [40] [41] . The number of CD8 + T cells producing TNF-a and both TNF-a and IFN-c in response to ex vivo peptide re-stimulation was maximal at day 7 p.i. but was still detectable on day 28 and day 56 p.i. in both fgl2 +/+ mice and fgl2 À/À mice (data not shown). than 10% and near equivalent in fgl2 À/À and fgl2 +/+ mice. However, after LCMV infection, the number of CD4 + PD-1 + T cells was reduced in fgl2 À/À mice compared with fgl2 +/+ mice (Fig. 5a,b) . In contrast to CD4 + cells, the number of PD-1 + CD8 + T cells was only reduced in fgl2 À/À mice compared with fgl2 +/+ mice at day 56 and day 100 p.i. (Fig. 5c,d) . Furthermore, the frequency of CD8 + Tet GP33-41 + T cells expressing PD-1 was reduced in fgl2 À/À mice compared with fgl2 +/+ mice (Fig. 5e,f) . Collectively, these data demonstrate that deletion of fgl2 leads to increased numbers of proinflammatory LCMV-specific CD8 + T cells and a reduced percentage of PD-1-expressing CD4 + and CD8 + T cells after LCMV cl-13 infection.
Fgl2
À/À mice generate increased numbers of T-cell memory cells and increased neutralizing antibody titres To assess virus-specific memory, splenic mononuclear cells were isolated from virus-infected mice and assessed by flow cytometry according to the gating strategy in the Supplementary material (Fig. S3) . The total number of CD8 + effector memory (Fig. 6a) , CD4 + effector memory (Fig. 6c) , CD8 + central memory (Fig. 6e ) and CD4 + central memory (Fig. 6f) 
cells was near equivalent in both fgl2
À/À and fgl2 +/+ uninfected mice. At day 56 following infection, fgl2 À/À mice had a 1Á8-fold increase in the number of CD8 + effector memory cells (Fig. 6a) ; a 1Á7-fold increase in CD8 + Tet Gp33-41 + effector memory cells (Fig. 6b) ; a twofold increase in CD4 + effector memory cells (Fig. 6c) ; a 21-fold increase in CD4 + Tet GP61-80 + effector memory cells (Fig. 6d) ; a twofold increase in CD8 + central memory cells (Fig. 6e) and a 2Á8-fold increase in CD4 + central memory cells (Fig. 6f) To determine that antibody treatment could prevent the development of chronic LCMV infection, mice were pre-treated with either PBS, isotype control antibodies, anti-FGL2 (9D8) or anti-FccRIIB /RIII (2.4G2) antibody alone, which had minimal effect on T-cell antiviral responses and none of these mice cleared LCMV cl-13 (data not shown). In contrast, pre-treatment of fgl2 +/+ mice with combination antibodies to FGL2 (9D8) and to FccRIIB/RIII (2.4G2) led to viral clearance (Fig. 8a) . Treated mice had a 3Á4-fold increase in numbers of CD8 + Tet GP33-41 + T cells (Fig. 8b) and a 2Á3-fold and twofold increase in numbers of IFN-c + CD8 + T cells to ex vivo peptide re-stimulation with the MHC-I-restricted peptides GP [33] [34] [35] [36] [37] [38] [39] [40] [41] and NP 396-404 , respectively, in comparison with PBS and isotype control treated mice (Fig. 8c) . The number of CD8 + T cells expressing PD-1 in LCMVinfected fgl2 +/+ mice treated with anti-FGL2 and antiFccRIIB/RIII was also reduced compared with PBS and isotype control treated mice (Fig. 8d) .
To examine whether antibodies to both FGL2 and FccRIIB/RIII could be an effective treatment for chronic infection, fgl2 +/+ mice, which had been previously infected with 2 9 10 6 PFU of LCMV cl-13 and had developed chronic disease, were treated on day 25 p.i. with 150 µg of 9D8 and 2.4G2 or PBS. Treatment was continued every 2 days until death on day 56 p.i. 44 At day 56 p.i., the number of CD3 + CD8 + Tet GP33-41 + in antibody-or PBS-treated mice was equivalent (Fig. 9a) IFN-c (Fig. 9b) and TNF-a in response to ex vivo peptide re-stimulation with GP [33] [34] [35] [36] [37] [38] [39] [40] [41] , NP 396-404 or GP 61-80 in contrast to PBS controls (Fig. 9c) . The number of CD3 + CD8 + (Fig. 9d) and CD3 + CD4 + T cells (Fig. 9e) expressing PD-1 was also significantly reduced in 2.4G2/9D8-treated mice. The frequency (%) of LCMV-specific (Tet GP33-41 + ) CD8 + T cells expressing PD-1 was also reduced in antibody-treated mice (Fig. 9f) . All mice treated with 2.4G2/9D8 cleared LCMV cl-13 by day 56 whereas PBS-treated control mice remained chronically infected (Fig. 9g) .
Discussion
Effective viral clearance requires a robust innate and adaptive antiviral immune response. 15, 44 A common feature of chronic infection is the lack of virus-specific T-cell responses, which is characterized by progressive functional T-cell exhaustion and deletion of virus-specific CD4 + and CD8 + T cells. Accounting at least in part for T-cell exhaustion is the overproduction of Treg cells 45 with a shift in the ratio of T-cell sustaining pro-inflammatory cytokines including interleukin-2, 46 Ligation of TIGIT to CD155 on APC leads to increased expression of FGL2, resulting in suppression of both Th1 and Th17 responses in vivo. 22 We and others have shown that FGL2 exerts its immunosuppressive activity following binding to FccRIIB/RIII, which is expressed primarily on APC. 49 The data generated in Fig. 4 show that the differences between fgl2 +/+ mice and fgl2 À/À mice emerge late in LCMV infection, which supports the contention that enhanced maturation of APC early in infection does not result in early priming of T cells, but rather is involved in the maintenance of virus-specific T cells late in infection when T-cell exhaustion has begun. Consistent with this is the finding that expression of programmed death-ligand 1 on APC isolated from LCMV-infected fgl2 +/+ and fgl2 In the present study, we examined the contribution of the FGL2-FccRIIB/RIII pathway to the establishment of chronic infection caused by LCMV cl-13. Plasma levels of FGL2 were significantly increased early after LCMV cl-13 infection and remained elevated at all time-points p.i. in contrast to infection with LCMV WE, which causes only a short self-limiting acute infection where FGL2 was only elevated early post infection and to a lesser extent. 33 Although we have reported that Treg cells are a major source of FGL2, other cells including macrophages and 
CD8
+ T cells can produce FGL2. Hence at this time we cannot unequivocally state that increased FGL2 in the plasma is solely due to production by Treg. 22, 51, 52 We used mice that were genetically deficient in fgl2 to study the effects of FGL2 on both the innate and adaptive antiviral immune response. Post LCMV cl-13 infection, To firmly establish that binding of FGL2 to its receptor FccRIIB/III accounted for changes in the innate and adaptive immune response to LCMV, mice chronically infected with LCMV were treated with antibody to FGL2 and FccRIIB/III alone or in combination. Although treatment with either antibody alone partially restored virusspecific T-cell responses, these mice failed to clear LCMV. In contrast, treatment with combination of antibodies to both FGL2 and FccRIIB/RIII led to restoration of CD4 + and CD8 + T-cell antiviral immunity and viral clearance. That antibody to FGL2 or FccRIIB/RIII alone did not completely restore antiviral immunity and viral clearance may reflect that the dose and/or frequency of antibody administration might have been insufficient to fully neutralize FGL2. By increasing the dose and timing of administration, viral clearance may be possible, although this was not examined here. Alternatively, it has been reported that antibody administration in the setting of chronic viral infection is less effective, which was thought to be due to the generation of immune complexes. [53] [54] [55] [56] The fgl2 À/À mice generated high titred neutralizing antibody at days 70 and 130 p.i. and robust virus-specific central and effector T-cell and B-cell memory responses co-incident with viral clearance in the plasma, lung and liver by day 56. The changes in antibody concentration seen in this study may reflect differences in follicular Tcell helper function, which was not examined in this study. Treatment of chronically infected fgl2 +/+ mice with combination antibody to FGL2 and FccRIIB/RIII resulted in similar results. Interestingly, virus could still be detected in the kidneys of fgl2 À/À mice and fgl2 +/+ mice treated with anti-FGL2 and anti-FccRIIB/RIII. The significance of this finding is not totally clear, although similar findings are seen in patients with chronic HCV infection who clear virus from the plasma. This finding may explain why transplantation of organs from virus-infected individuals who have cleared the virus from the plasma is known to be associated with a risk of virus transmission. 57 This is supportive of the concept that establishment of a sustained virological response in HCV infection leads to immunological control of infection but not total viral eradication. 58 Wherry et al. have previously reported an increase in fgl2 mRNA transcripts in effector and exhausted virusspecific T cells and expression of FccRIIB on effector T cells. 24 In chronic infection, patients with chronic HBV and HCV infection have increased plasma levels of FGL2, as well as increased frequencies of Treg cells expressing FGL2. 50, 59 Increased FGL2 during chronic infection could influence T-cell responsiveness to antigen directly by binding FccRIIB on activated effector T cells and promoting T-cell exhaustion or indirectly by binding Fc receptors on APC, preventing DC maturation and antigen presentation. In a study by Starbeck-Miller et al., expression of FccRIIB following challenge with LCMV cl-13 was associated with reduced cytotoxicity and reduced secondary expansion of memory CD8 + T cells. 23 It is known that FccRIIB is an inhibitory receptor widely expressed on DC and B cells and signals through immunoreceptor tyrosine-based inhibition motif phosphorylation, which causes the recruitment of SHIP leading to reduction in activation of DC and apoptosis of B cells. 25 Additionally, FGL2 has been shown to augment immunosuppression by increasing expression levels of PD-1 and CD39, expanding the frequency of M2 macrophages through FccRIIB, while increasing the number of myeloid-derived suppressor cells and Treg cells. 60 In summary, the data presented here demonstrate an important role for FGL2 and FccRIIB/RIII in the development of chronic LCMV cl-13 infection. Here, we show that targeted deletion of fgl2 and treatment of fgl2 +/+ mice with neutralizing antibodies to FGL2 and FccRIIB/RIII restores T-cell and B-cell antiviral immunity to LCMV cl-13, resulting in viral clearance. The studies support the concept that targeting the FGL2-FccRIIB/RIII pathway might be useful to treat patients with chronic viral infections including HBV, HCV and HIV, which are known to induce expression of FGL2 and FccRIIB/RIII.
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